Protective effect of saponins from Panax notoginseng against doxorubicin-induced cardiotoxicity in mice

Planta Medica

Volumn 74, Issue 3, 2008, Pages 203-209

  Liu, Li ^a   Shi, Run ^a   Shi, Qiang ^a   Cheng, Yiyu ^a   Huo, Yang ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Araliaceae; Cardioprotective drug; Cardiotoxicity; Doxorubicin; Panax notoginseng (Burk.) F. H. Chen; Triterpene dammarene saponins

Indexed keywords

AMIFOSTINE; ANTIOXIDANT; CATALASE; CREATINE KINASE; CREATINE KINASE MB; DOXORUBICIN; GINSENOSIDE RB 1; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RG 1; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; NOTOGINSENOSIDE R 1; PANAX NOTOGINSENG EXTRACT; SAPONIN DERIVATIVE; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARDIOTOXICITY; CELL LINE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; HEART; HEART FUNCTION; HEART PROTECTION; HEART VENTRICLE CONTRACTILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; PANAX NOTOGINSENG;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUGS, CHINESE HERBAL; HERB-DRUG INTERACTIONS; HUMANS; MALE; MICE; MICE, INBRED ICR; MYOCARDIUM; PANAX NOTOGINSENG; PHYTOTHERAPY; RANDOM ALLOCATION; RHIZOME; SAPONINS;

ARALIACEAE; MUS; PANAX NOTOGINSENG;

EID: 41349101738     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1034303     Document Type: Article

References (33)

1. Ng TB. Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol 2006; 58: 1007-19
2. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978; 62: 955-61
3. Xu MF, Tang PL, Qian ZM, Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001; 68: 889-901
4. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 2002; 234-235: 119-24
5. Pessah IN. Calcium release channel of sarcoplasmic reticulum: an important target for doxorubicin-mediated cardiotoxicity. Adv Exp Med Biol 1992; 311: 409-10
6. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006; 41: 389-405
7. Li L, Zhang JL, Sheng YX, Guo DA, Wang Q, Guo HZ. Simultaneous quantification of six major active saponins of Panax notoginseng by high-performance liquid chromatography-UV method. J Pharm Biomed Anal 2005; 38: 45-51
8. Liu X, Chua CC, Gao J, Chen Z, Landy CL, Hamdy R et al. Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 2004; 286: H933-9
9. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 1984; 142: 290-6
10. Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta 1991; 196: 143-51
11. Redegeld FA, van Opstal MA, Houdkamp E, van Bennekom WP. Determination of glutathione in biological material by flow-injection analysis using an enzymatic recycling reaction. Anal Biochem 1988; 174: 489-95
12. El-Demerdash E, Ali AA, Sayed-Ahmed MM, Osman AM. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 2003; 52: 411-6
13. Liu X, Chen Z, Chua CC, Ma YS, Youngberg CA, Hamdy R et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2002; 283: H254-63
14. Berthiaume JM, Oliveira PJ, Fariss MW, Wallace KB. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 2005; 5: 257-67
15. Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, Ucar M et al. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 2004; 24: 47-52
16. Sadzuka Y, Sugiyama T, Shimoi K, Kinae N, Hirota S. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett 1997; 92: 1-7
17. Jagetia GC, Reddy TK, Malagi KJ, Nayak BS, Naidu MB, Ravikiran PB et al. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity. Phytother Res 2005; 19: 772-8
18. Mohan IK, Kumar KV, Naidu MU, Khan M, Sundaram C. Protective effect of CardiPro against doxorubicin-induced cardiotoxicity in mice. Phytomedicine 2006; 13: 222-9
19. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52
20. Herman EH, el-Hage A, Ferrans VJ. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 1988; 92: 42-53
21. Bast A, Kaiserova H, den Hartog GJ, Haenen GR, van der Vijgh WJ. Protectors against doxorubicin-induced cardiotoxicity: Flavonoids. Cell Biol Toxicol 2007; 23: 39-47
22. Jahnukainen K, Jahnukainen T, Salmi TT, Svechnikov K, Eksborg S, Soder O. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. Cancer Res 2001; 61: 6423-7
23. Catino A, Crucitta E, Latorre A, Sambiasi D, Calabrese P, Lorusso V. Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin. Oncol Rep 2003; 10: 163-7
24. Nazeyrollas P, Frances C, Prevost A, Costa B, Lorenzato M, Kantelip JP et al. Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment. Anticancer Res 2003; 23: 405-9
25. Dragojevic-Simic VM, Dobric SL, Bokonjic DR, Vucinic ZM, Sinovec SM, Jacevic VM et al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs 2004; 15: 169-78
26. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65: 128-35
27. Li X, Chen JX, Sun JJ. Protective effects of Panax notoginseng saponins on experimental myocardial injury induced by ischemia and reperfusion in rat. Zhongguo Yao Li Xue Bao 1990; 11: 26-9
28. Gao BY, Li XJ, Liu L, Zhang BH. Effect of panaxatriol saponins isolated from Panax notoginseng (PTS) on myocardial ischemic arrhythmia in mice and rats. Yao Xue Xue Bao 1992; 27: 641-4
29. Dan HX, Zhang BH, Xie SR, Yao JA, Jia JN. Effects of panaxadiol saponins isolated from Panax notoginseng on intracellular and extracellular calcium. Zhongguo Yao Li Xue Bao 1993; 14 (Suppl): S22-5
30. Xiong ZG, Sun JJ. Effects of Panax notoginseng saponin Rb1 and Rg1 on myocardial action potential and slow inward current. Zhongguo Yao Li Xue Bao 1989; 10: 520-2
31. Asayama J, Tanaka T, Tatsumi T, Nakagawa C, Kobara M, Matoba S et al. Effect of doxorubicin on postrest contraction in isolated rat hearts. J Cardiovasc Pharmacol 1995; 26: 693-7
32. Yang ZG, Sun HX, Ye YP. Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis. Chem Biodivers 2006; 3: 187-97
33. Wang CZ, Luo X, Zhang B, Song WX, Ni M, Mehendale S et al. Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother Pharmacol 2007; 60: 69-79